Australia's Testosterone Gender Gap: Women Face Higher Costs for Vital Therapy

The case of Claire, an Australian woman whose quality of life was restored through testosterone therapy, highlights a growing friction point in the Australian healthcare system: the "pink tax" on essential hormonal treatments. While testosterone is traditionally categorized as a male hormone, it is the most prevalent biologically active steroid in the female body prior to menopause. For women suffering from Hypoactive Sexual Desire Disorder (HSDD), a condition characterized by a distressing lack of libido, testosterone therapy is often the only effective clinical intervention. However, the Australian Pharmaceutical Benefits Scheme (PBS) currently lacks a subsidized pathway for female-specific testosterone, leaving women to bear the full market cost while men receive similar treatments at a fraction of the price.

The disparity is rooted in the regulatory and reimbursement history of hormone replacement therapy (HRT). For decades, testosterone research focused almost exclusively on male hypogonadism. It wasn't until the 2019 Global Consensus Position Statement, authored by leading international medical societies, that the clinical community reached a formal agreement on the safety and efficacy of testosterone for postmenopausal women. Despite this clinical validation, the transition from medical consensus to public subsidy has been slow. In Australia, the Therapeutic Goods Administration (TGA) has approved female-specific formulations, but without a recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC) for a PBS listing, these products remain in the "private script" category.

“

Women who can afford $80 to $120 for a two-month supply of specialized cream can access treatment, while those in lower socioeconomic brackets are either priced out or forced to use "off-label" male products.

This financial barrier creates a two-tiered system of care. Women who can afford $80 to $120 for a two-month supply of specialized cream can access treatment, while those in lower socioeconomic brackets are either priced out or forced to use "off-label" male products. Using male-strength gels for women is clinically fraught; the concentrations are designed for male physiology, making it extremely difficult for women to measure the tiny doses required—often one-tenth of a male dose. This leads to a higher risk of virilization side effects, such as acne, hair growth, or voice deepening, further complicating the patient experience and safety profile.

From a market perspective, the lack of subsidy limits the commercial incentive for pharmaceutical companies to bring more female-specific products to the Australian market. Currently, a single TGA-approved option for women dominates the niche. Without competition or government negotiation on price through the PBS, the cost remains static and high. Advocacy groups, including the Australasian Menopause Society, have been increasingly vocal about the need for the PBAC to recognize HSDD as a legitimate clinical indication for subsidized testosterone, arguing that sexual health is a fundamental component of overall well-being and healthy aging.